News for 'CTIX' - (Cellceutix to Pursue Significant

New Post Public Reply Private Reply Replies (2) Message Board

Nov 4, 2013 at 7:15 AM

News for 'CTIX' - (Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin)

BEVERLY, MA, Nov 04, 2013 (Marketwired via COMTEX) -- Cellceutix Corporation
(OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company
developing innovative therapies in oncology, dermatology, and antibiotic
applications, is pleased to inform shareholders that the Company is conducting
experiments on Brilacidin(TM), its lead antibiotic compound, for ophthalmic
infections, including keratitis and conjunctivitis. Cellceutix estimates the
market potential for these indications well in excess of $1 billion and has its
antibiotic team expanding upon the significant amount of preclinical research
that has been conducted on Brilacidin for these conditions.

Prior to the Cellceutix acquisition of PolyMedix in September, lab studies
conducted at the Charles T. Campbell Ophthalmic Microbiology Laboratory at the
University of Pittsburgh demonstrated the safety, tolerability and broad
activity of Brilacidin against clinically important Gram-positive and
Gram-negative pathogens, including drug-sensitive and drug-resistant clinical
isolate strains of ocular infections.

Pharmacokinetic studies were conducted at Iris Pharma, a Contract Research
Organization based in France, showing that Brilacidin has a high residence time
on the surface of the eye with negligible systemic exposure. This indicates that
effective therapeutic concentrations of Brilacidin can be maintained in the eye
with infrequent treatments.

As a defensin-mimetic, Brilacidin is a completely novel class of antibiotics and
a platform for a broad spectrum of indications in an area of urgent need for new
drugs. Topical ophthalmic anti-infective drugs that are used today for keratitis
and conjunctivitis have serious limitations due to bacterial resistance and
serious side effects. For example, although exclusive of topical uses of
fluoroquinolones for eye and ear infections, the U.S. Food and Drug
Administration in August required that drug labels and Medication Guides for all
systemic fluoroquinolone antibacterial drugs be updated to describe the
potential serious side effect of peripheral neuropathy.

"The Brilacidin ocular data is highly exciting. Our new research program
focusing on ocular drugs is the next step in expanded uses of Brilacidin that we
believe will develop into a blockbuster antibiotic drug franchise," said Dr.
Krishna Menon, Chief Scientific Officer at Cellceutix. "We have a litany of
clinical and preclinical data on Brilacidin. Our research staff is currently
growing epithelial cells for testing so that we can formulate Brilacidin as a
topical solution with efficient penetration of the epithelium to maximize
clinical results."

"We are going to continue aggressively moving forward with Brilacidin as the
current biotechnology environment is desperate for new therapeutics," added Leo
Ehrlich, Chief Executive Officer at Cellceutix. "Reuters reported only yesterday
that Swiss drugmaker Roche is poised to get back into antibiotics because of a
novel drug that they want to develop to tackle drug-resistant bacteria. Simply,
a novel drug has phenomenal sales potential. Johnson & Johnson's Levaquin was
generating $1.3 billion in sales before it came off patent. Cubist's Daptomycin
for ABSSSI only comprised 8 percent of total doses, yet controlled approximately
82 percent of total sales in that market. The majority of approved antibiotics
today are legacy drugs or variations of them for which resistance is constantly
evolving. Our plan is to establish Brilacidin as the next generation antibiotic.
It has opened a door to a multi-billion-dollar pathway and we are not just
looking at it, we are part way through it and moving as quickly as possible to
establish a leadership position."

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company
under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical
company developing innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world class portfolio of compounds
and is now engaged in advancing its compounds and seeking strategic
partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1
clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth
Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce
activation of p53, often referred to as the "Guardian Angel Gene" due to its
crucial role in controlling cell mutations. Cellceutix is planning a Phase 2
clinical trial with its novel compound Brilacidin-OM for the prevention and
treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has
shown in the laboratory to reduce the occurrence of severe ulcerative oral
mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug
Prurisol is being readied for a Phase 2/3 clinical trial at sites in the U.S.
and Europe. Prurisol is a small molecule that acts through immune modulation and
PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is set to begin a
Phase 2b trial in the first half of 2014 for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. Brilacidin has the potential to be a
single-dose therapy for multi-drug resistant bacteria or a dosing regimen that
is shorter than currently marketed antibiotics. Cellceutix has formed research
collaborations with world renowned research institutions in the United States
and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical
Center, and the University of Bologna. More information is available on the
Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause Cellceutix's
actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. Cellceutix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements are Cellceutix's need for, and the
availability of, substantial capital in the future to fund its operations and
research and development; including the amount and timing of the sale of shares
of common stock to Aspire Capital; the fact that Cellceutix's compounds may not
successfully complete pre-clinical or clinical testing, or be granted regulatory
approval to be sold and marketed in the United States or elsewhere. A more
complete description of these risk factors is included in Cellceutix's filings
with the Securities and Exchange Commission. You should not place undue reliance
on any forward-looking statements. Cellceutix undertakes no obligation to
release publicly the results of any revisions to any such forward-looking
statements that may be made to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events, except
as required by applicable law or regulation.

Contact:

INVESTOR AND MEDIA CONTACT:

Cellceutix Corp.

Leo Ehrlich

(978) 236-8717

Email Contact

SOURCE: Cellceutix

(C) 2013  Marketwire L.P.  All rights reserved.

-0-

SUBJECT CODE:     Pharmaceuticals and Biotech:Biotech

                  Pharmaceuticals and Biotech:Trials

                  Pharmaceuticals and Biotech:Equipment and Supplies

                  Pharmaceuticals and Biotech

rugs

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vensure Launches Nationwide Background Casting Service

Vensure Dives into the World of Background Casting You ever consider just how chaotic a film or TV set can get? One minute things are all glitz and glam, and the next, it's pure mayhem as everything descends into a frenzied dance of coordination chaos. That's the circus of background casting for ya. Vensure's latest venture, Vensure Casting, throws its hat in the ring,...

Customized Anti-Aging Plans Revealed: Botox to Microneedling

Intricacies of Aging: Beyond One-Size-Fits-All So you've hit a point in life where those wrinkles and sagging skin aren't just brushing off with a night's sleep. Enter Dr. Sherif Salama with his treasure trove of options fitting for the fussy nature of skin. The Aging Conundrum: Multifaceted Challenges Aging isn't a one-trick pony. Wrinkles crop up, volume disappears,...

Tom Doyle Takes Helm at Gallagher's HR Consulting

Leadership Shifts in Gallagher's Upper Echelons What a shake-up at Arthur J. Gallagher & Co.! The power torch is officially passing over in its Benefits & HR Consulting Division. Come January 1, 2027, Tom Doyle is strapping in as the new CEO, taking over from William F. "Bill" Ziebell. Now, don't get too teary-eyed—Ziebell's not vanishing into thin air. Instead, he's...

Winter Roof Woes: How to Handle Ice and Snow Load

Understanding Roof Load Limits You don't have to be in the roofing business to know that Central NY doesn't mess around when winter hits. Michael Majeski, a name trusted in Watertown, NY, is sounding the alarm on how snow and ice can either shake a roof or break it. Talking about roof 'load limits' might sound all fancy, but in plain talk, it's about knowing when your...

SightMD Adds Top Cornea Specialist to Yonkers Team

Expanding Expertise in Westchester Today's eye care landscape just got a bit tighter up in Yonkers. SightMD's hauled in a new ace—Dr. Brittany M. Perzia. This isn't your run-of-the-mill hire. The good doctor packs a solid punch in Cornea & External Disease, aiming her skills at the folks around Westchester. It's not just about the numbers with her, though. Her resume's...

Qapture's Institutional Stablecoin Venture Unveiled

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...

Independents' Election Broadcast: A Historic Shift

Independents Take Center Stage on Election Night 2026 Over the years, I've seen plenty of unexpected movements in the market, but this is something unique—a seismic shift, not in finance, but in the political landscape. Election Night 2026 is shaping up to be a real game-changer, as independents step away from the sidelines and demand attention. It's a first-of-its-kind...

MemorialCare Expands Cutting-Edge GERD Treatment Options

Shifting the GERD Treatment Paradigm While everyone's talking about breakthrough technologies like AI and blockchain in medicine, MemorialCare seems to have quietly flipped the script on treating gastroesophageal reflux disease (GERD). They're sidestepping conventional maneuvers by embracing two procedures known as transoral incisionless fundoplication (TIF) and its...

PATEO Drives In-Car AI Forward with NVIDIA Power

Revolutionizing In-Vehicle AI with Big Names Boy, driving ain't what it used to be, and PATEO's latest adventure has a lot to do about it. They've hooked up with some major players like NVIDIA and ByteDance to really shake up the in-car AI scene. We're not just talking bells and whistles, but a true reinvention trying to blend AI straight into our daily grind on the road....

VAB's Pharma Ad Guide: Emerging Trends and Insights

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...